In this episode of the Syneos Health Podcast: Site Realities series, Tammy D’Lugin-Monroe, Head of Sites and Patient Solutions at Syneos Health, sits down with Mimi Fenton, MPH, PhD, CEO of Cedar Health Research, to explore what it truly means to operate on the front lines of clinical research. Drawing on her experience across pharma, CRO and site leadership, Mimi offers a candid view into the operational, financial and human realities that shape today’s clinical trial landscape.

The conversation highlights the growing disconnect between protocol design and real-world execution—and how sponsors and CROs can close that gap by engaging sites earlier, simplifying technology integration and prioritizing patient-centered approaches. Mimi also underscores the critical role of trust, emphasizing that sites serve as the face of the sponsor within communities and are essential to improving access, diversity and retention in clinical trials.

From the burden of fragmented technology to the importance of long-term partnerships over transactional relationships, this episode offers practical insights on how the industry can better collaborate to accelerate trial delivery and improve outcomes for patients.

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this episode of The Syneos Health Podcast, Conversations on Commercialization, Tyler Cowan, VP, Commercial speaks with Paul Rittman, President and General Manager of Almirall US, about how payer consolidation and PBM influence are reshaping dermatology commercialization.

They discuss how pharmaceutical companies must adapt launch strategy, market access planning and clinical differentiation to succeed in today’s competitive specialty landscape. The conversation explores the growing role of digital engagement, direct-to-consumer (DTC) strategy, telehealth and cash-pay models in improving patient access.

Listeners will gain practical insights into how innovation, payer strategy and patient-centric commercialization drive success in dermatology and specialty pharma.

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this episode, Lynn Hamilton speaks with Stuart Goodall, Senior Vice President at Syneos Health, about how regulatory functions are evolving in response to growing complexity, accelerating timelines and emerging technologies. With more than 35 years of global experience, Stuart offers an unfiltered perspective on what regulatory and medical writing teams need to succeed today—and how to scale smartly for what’s next.

Topics explored include:

· The shift from information advantage to decision advantage in regulatory intelligence

· How AI is changing—not replacing—medical writing and regulatory operations

· What sponsors need to consider when building scalable, tech-enabled models

· Why FSP is no longer just transactional and how strategic partnerships are redefining value

· Why storytelling and judgment remain irreplaceable in an automated world

Whether you're exploring your next medical writing solution or rethinking regulatory infrastructure, this conversation offers grounded insights with a forward-looking lens.

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.